Testosterone treatment is a potent tumor promoter for the rat prostate

Endocrinology

Volumn 155, Issue 12, 2014, Pages 4629-4633

  Bosland, Maarten C ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; METHYLNITROSOUREA; TESTOSTERONE;

ANIMAL; CARCINOMA; CHEMICALLY INDUCED; DOSE RESPONSE; MALE; PROSTATE TUMOR; RAT;

ANDROGENS; ANIMALS; CARCINOMA; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; METHYLNITROSOUREA; PROSTATIC NEOPLASMS; RATS; TESTOSTERONE;

EID: 84914132642     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2014-1688     Document Type: Article

References (45)

1. Baillargeon J, Urban RJ, Ottenbacher KJ, Pierson KS, Goodwin JS. Trends in androgen prescribing in the United States, 2001 to 2011. JAMA Intern Med. 2013;173:1465-1466.
2. Layton JB, Li D, Meier CR, et al. Testosterone lab testing and initiation in the United Kingdom and the United States, 2000 to 2011. J Clin Endocrinol Metab. 2014;99:835-842.
3. Rosenthal E. A push to sell testosterone gels troubles doctors. The New York Times. October 15, 2013. http://www.nytimes.com/ 2013/10/16/us/a-push-to-sell-testosterone-gels-troubles-doctors.html.
4. Schwartz LM, Woloshin S. Low "T" as in "template": how to sell disease. JAMA Intern Med. 2013;173:1460-1462.
5. Brand TC, Canby-Hagino E, Thompson IM. Testosterone replacement therapy and prostate cancer: a word of caution. Curr Urol Rep. 2007;8:185-189.
6. Bain J. Testosterone and the aging male: to treat or not to treat? Maturitas. 2010;66:16-22.
7. Khera M, Crawford D, Morales A, Salonia A, Morgentaler A. Anew era of testosterone and prostate cancer: from physiology to clinical implications. Eur Urol. 2014;65:115-123.
8. Xu L, Freeman G, Cowling BJ, Schooling CM. Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. BMC Med. 2013;11:108.
9. Vigen R, O'Donnell CI, Barón AE, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. 2013;310:1829-1836.
10. Finkle WD, Greenland S, Ridgeway GK, et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS One. 2014;9:e85805.
11. Emmelot-Vonk MH, Verhaar HJ, Nakhai Pour HR, et al. Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial. JAMA. 2008;299:39-52.
12. Sakr WA, Grignon DJ, Crissman JD, et al. High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. In Vivo. 1994;8:439-443.
13. Gann PH, Hennekens CH, Ma J, Longcope C, Stampfer MJ. Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst. 1996;88:1118-1126.
14. Hyde Z, Flicker L, McCaul KA, et al. Associations between testosterone levels and incident prostate, lung, and colorectal cancer. A population-based study. Cancer Epidemiol. Biomarkers Prev. 2012;21:1319-1329.
15. Eaton NE, Reeves GK, Appleby PN, Key TJ. Endogenous sex hormones and prostate cancer: a quantitative review of prospective studies. Br J Cancer. 1999;80:930-934.
16. Endogenous Hormones and Prostate Cancer Collaborative Group, Roddam AW, Allen NE, Appleby P, Key TJ. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst. 2008;100:170-183.
17. Berry PA, Maitland NJ, Collins AT. Androgen receptor signalling in prostate: effects of stromal factors on normal and cancer stem cells. Mol Cell Endocrinol. 2008;288:30-37.
18. Cunha GR. Mesenchymal-epithelial interactions: past, present, and future. Differentiation. 2008;76:578-586.
19. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349:215-224.
20. Andriole GL, Bostwick DG, Brawley OW,et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med. 2010;362:1192-1202.
21. Morgentaler A. Testosterone and prostate cancer: what are the risks for middle-aged men? Urol Clin North Am. 2011;38:119-124.
22. Schultheiss D, Machtens S, Jonas U. Testosterone therapy in the ageing male: what about the prostate? Andrologia. 2004;36:355-365.
23. Noble RL. The development of prostatic adenocarcinoma in Nb rats following prolonged sex hormone administration. Cancer Res. 1977;37:1929-1933.
24. Pollard M, Luckert PH. Autochthonous prostate adenocarcinomas in Lobund-Wistar rats: a model system. Prostate. 1987;11:219-227.
25. Pollard M, Luckert PH, Schmidt MA. Induction of prostate adenocarcinomas in Lobund Wistar rats by testosterone. Prostate. 1982;3:563-568.
26. Hoover DM, Best KL, McKenney BK, Tamura RN, Neubauer BL. Experimental induction of neoplasia in the accessory sex organs of male Lobund-Wistar rats. Cancer Res. 1990;50:142-146.
27. Pollard M, Luckert PH. Prostate cancer in a Sprague-Dawley rat. Prostate. 1985;6:389-393.
28. Pour PM, Stepan K. Induction of prostatic carcinomas and lower urinary tract neoplasms by combined treatment of intact and castrated rats with testosterone propionate and N-nitrosobis(2-oxopropyl) amine. Cancer Res. 1987;47:5699-5706.
29. Bosland MC, Dreef-Van Der Meulen HC, Sukumar S, et al. Multistage prostate carcinogenesis: the role of hormones. Princess Takamatsu Symp. 1991;22:109-123.
30. McCormick DL, Rao KV, Dooley L, et al. Influence of N-methyl-N-nitrosourea, testosterone, and N-(4-hydroxyphenyl)-all-transretinamide on prostate cancer induction in Wistar-Unilever rats. Cancer Res. 1998;58:3282-3288.
31. Shirai T, Tamano S, Kato T, Iwasaki S, Takahashi S, Ito N. Induction of invasive carcinomas in the accessory sex organs other than the ventral prostate of rats given 3,2-dimethyl-4-aminobiphenyl and testosterone propionate. Cancer Res. 1991;51:1264-1269.
32. de Groot AP, Feron VJ, Immel HR. Induction of hyperplasia in the bladder epithelium of rats by a dietary excess of acid or base: implications for toxicity/carcinogenicity testing. Food Chem Toxicol. 1988;26:425-434.
33. Arts CJ, van Baak MJ, den Hartog JM. Control system for detection of the illegal use of naturally occurring steroids in calves. J Chromatogr. 1991;564:429-444.
34. Slaga TJ. Overview of tumor promotion in animals. Environ Health Perspect. 1983;50:3-14.
35. Pitot HC, Loeb DD. Fundamentals of Oncology. New York, NY-Basel, Switzerland: Marcel Dekker; 2002.
36. IARC. Pharmaceuticals. Volume 100 A. A review of human carcinogens. IARC Monogr Eval Carcinog Risks Hum. 2012;100:1-401.
37. McCormick DL, Rao KV, Johnson WD, Bosland MC, Lubet RA, Steele VE. Null activity of selenium and vitamin e as cancer chemopreventive agents in the rat prostate. Cancer Prev Res (Phila). 2010;3:381-392.
38. McCormick DL, Johnson WD, Haryu TM, Bosland MC, Lubet RA, Steele VE. Null effect of dietary restriction on prostate carcinogenesis in the Wistar-Unilever rat. Nutr Cancer. 2007;57:194-200.
39. McCormick DL, Johnson WD, Bosland MC, Lubet RA, Steele VE. Chemoprevention of rat prostate carcinogenesis by soy isoflavones and by Bowman-Birk inhibitor. Nutr. Cancer. 2007;57:184-193.
40. McCormick DL, Johnson WD, Kozub NM, et al. Chemoprevention of rat prostate carcinogenesis by dietary 16α-fluoro-5-androsten-17-one (fluasterone), a minimally androgenic analog of dehydroepiandrosterone. Carcinogenesis. 2007;28:398-403.
41. Rao KV, Johnson WD, Bosland MC, et al. Chemoprevention of rat prostate carcinogenesis by early and delayed administration of dehydroepiandrosterone. Cancer Res. 1999;59:3084-3089.
42. McCormick DL, Rao KV, Steele VE, Lubet RA, Kelloff GJ, Bosland MC. Chemoprevention of rat prostate carcinogenesis by 9-cis-retinoic acid. Cancer Res. 1999;59:521-524.
43. McCormick DL, Johnson WD, Lubet RA, Steele VE, Bosland MC. Differential chemopreventive activity of the antiandrogen, flutamide, and the antiestrogen, tamoxifen, in the rat prostate. Proc Am Assoc Cancer Res. 2002;43:640.
44. Bosland MC. A perspective on the role of estrogen in hormone-induced prostate carcinogenesis. Cancer Lett. 2012;334:28-33.
45. Marks LS, Mazer NA, Mostaghel E, et al. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA. 2006;296:2351-2361.